Le 13 octobreOctober 13, 2020) Sire Bioscience Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common shares for every ten (10) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 42,423,597 common shares.


The name and symbol will not change.

Please note that all open orders will be cancelled at the close of business on October 14, 2020. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

Sire Bioscience Inc. a annoncé un regroupement de ses actions ordinaires émises et en circulation sur la base d’une (1) action ordinaire post-consolidation pour chaque dix (10) actions ordinaires pré-consolidation.

Par conséquent, les actions en circulation de la société seront réduites à environ 42 423 597 actions ordinaires.

Le nom et le symbole ne changeront pas.

Veuillez noter que toutes les commandes ouvertes seront annulées à la fermeture des bureaux le 14 octobre 2020. Il est rappelé aux courtiers de ressaisir leurs commandes en tenant compte du regroupement d’actions.

Trading on a Consolidated Basis/Négociation sur une base consolidée: le 15 octobre/October 2020
Record Date/Date d’enregistrement: le 16 octobre/October 2020
Symbol/Symbole: SIRE
NEW/NOUVEAU CUSIP: 82964J209
NEW/NOUVEAU ISIN: CA82964J2092
Old/Vieux CUSIP & ISIN: 82964J100/CA82964J1003

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

(TheNewswire)

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.

“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide shareholders with the following commercial update:

Vape Cartridges Powered by OILSTM now Available in the Provincial Retail Market

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www . rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES /

Funds will be used for enhancements to manufacturing facility, in preparation for launch of infused beverages in Canadian market

Keep reading... Show less